ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

A Randomized, Open-Label, Multicenter, Phase 3 Study of High-Dose Vitamin C Plus FOLFOX ? Bevacizumab versus FOLFOX ? Bevacizumab in Unresectable Untreated Metastatic Colorectal Cancer (VITALITY Study)

Wang, Feng; He, Ming -Ming; Xiao, Jian; Zhang, Yan-Qiao; Yuan, Xiang-Lin; Fang, Wei-Jia; Zhang, Yan; Wang, Wei; Hu, Xiao-Hua; Ma, Zhi-Gang; Yao, Yi-Chen; Zhuang, Zhi-Xiang; Zhou, Fu-Xiang; Ying, Jie-Er; Yuan, Ying; Zou, Qing-Feng; Guo, Zeng-Qing; Wu, Xiang-Yuan; Jin, Ying; Mai, Zong-Jiong; Wang, Zhi-Qiang; Qiu, Hong; Guo, Ying; Shi, Si -Mei; Chen, Shuang-Zhen; Luo, Hui-Yan; Zhang, Dong-Sheng; Wang, Feng-Hua*; Li, Yu-Hong; Xu, Rui-Hua*佛山市第一人民医院; 广州医学院; 华中科技大学; 哈尔滨医科大学; 浙江大学; 苏州大学; 武汉大学; 中国医学科学院; 中山大学; 6; 1
Clinical Cancer Research2022-10-1DOI: 10.1158/1078-0432.CCR-22-0655
6被引12阅读
引用收藏
分享

摘要

Purpose: To compare the efficacy and safety of high-dose vitamin C plus FOLFOX f bevacizumab versus FOLFOX f bevacizumab as first-line treatment in patients with metastatic colorectal cancer (mCRC).Patients and Methods: Between 2017 and 2019, histologically confirmed patients with mCRC (n = 442) with normal glucose-6-phosphate dehydrogenase status and no prior treatment for met-astatic disease were randomized (1:1) into a control (FOLFOX f bevacizumab) and an experimental [high-dose vitamin C (1.5 g/kg/ d, intravenously for 3 hours from D1 to D3) plus FOLFOX f bevacizumab] group. Randomization was based on the primary tumor location and bevacizumab prescription.Results: The progression-free survival (PFS) of the experimental group was not superior to the control group [median PFS, 8.6 vs. 8.3 months; HR, 0.86; 95% confidence interval (CI), 0.70-1.05; P = 0.1]. The objective response rate (ORR) and overall survival (OS) of the experimental and control groups were similar (ORR, 44.3% vs. 42.1%; P = 0.9; median OS, 20.7 vs. 19.7 months; P = 0.7). Grade 3 or higher treatment-related adverse events occurred in 33.5% and 30.3% of patients in the experimental and control groups, respec-tively. In prespecified subgroup analyses, patients with RAS muta-tion had significantly longer PFS (median PFS, 9.2 vs. 7.8 months; HR, 0.67; 95% CI, 0.50-0.91; P = 0.01) with vitamin C added to chemotherapy than with chemotherapy only.Conclusions: High-dose vitamin C plus chemotherapy failed to show superior PFS compared with chemotherapy in patients with mCRC as first-line treatment but may be beneficial in patients with mCRC harboring RAS mutation.

学科与关键词

关键词
I CLINICAL-TRIALASCORBIC-ACIDSUPPLEMENTAL ASCORBATESUPPORTIVE TREATMENTSURVIVAL TIMESCELLSPHARMACOKINETICSPROLONGATIONIMPROVESKRAS
相关
加载中…
  • A randomized, open-label, multicenter, phase III study of high-dose vitamin C plus FOLFOX plus /- bevacizumab versus FOLFOX plus /- bevacizumab as first-line treatment in patients with unresectable metastatic colorectal cancer
    Wang, F.; Xiao, J.; Zhang, Y.; Yuan, X.; He, M.; Fang, W.; Zhang, Y.; Wang, W.; Hu, X.; Ma, Z.; Yao, Y.; Zhuang, Z.; Zhou, F.; Ying, J.; Yuan, Y.; Zou, Q.; Guo, Z.; Wu, X.; Jin, Y.; Mai, Z.; Guo, Y.; Xu, R.ESMO 24th World Congress on Gastrointestinal Cancer, Barcelona, SPAIN, 2022-06-29 To 2022.
  • A Randomized Phase III Study of Anlotinib Versus Bevacizumab in Combination With CAPEOX as First-Line Therapy for RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Clinical Trial Protocol
    He, Jinjie; Liu, Yue; Liu, Chengcheng; Hu, Hanguang; Sun, Lifeng; Xu, Dong; Li, Jun; Wang, Junye; Chen, Xiaobing; Lin, Rongbo; Jiang, Yi; Zhang, Yanqiao; Zhang, Weisheng; Cheng, Ying; Wu, Xiaohong; Fang, Mingzhi; Li, Enxiao; Xu, Ye; Chen, Ye; Li, Jiayi; Cui, Yanyan; Pan, Zhanyu; Zhang, Songnan; Yuan, Ying; Ding, Kefeng*TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2023, 22: 15330338231152350.被引 2
  • Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study
    Meng, Qianhao; Zhao, Jian; Yu, Yuanyuan; Wang, Ke; Ren, Jing; Xu, Chang; Wang, Yusheng*; Wang, Guangyu*BMC CANCER, 2023, 23(1): 191.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
Clinical Cancer Research
发表日期
2022-10-01
卷期
第 28 卷, 第 19 期
页码
4232-4239
DOI
10.1158/1078-0432.CCR-22-0655
语言
ENGLISH
期刊等级
1区
成果收录
SCIE
资助标注
Sun Yat-sen University Clinical Research 5010 Program; National Natural Science Foundation of China; Science and Technology Program of Guangdong; Science and Technology Program of Guangzhou; Program of Guangdong Provincial Clinical Research Center for Digestive Diseases; [2018014]; [81930065]; [82173128]; [2019B020227002]; [201904020046]; [2020B1111170004]

作者

  • W

    Wang, Feng (第一作者)

  • H

    He, Ming -Ming

    sun yat sen univ · chinese acad med sci

查看全部 30 位作者收起作者
  • X

    Xiao, Jian

    6 · sun yat sen univ

  • Z

    Zhang, Yan-Qiao

  • Y

    Yuan, Xiang-Lin

    huazhong univ sci & technol

  • F

    Fang, Wei-Jia

    1 · zhejiang univ

  • Z

    Zhang, Yan

  • W

    Wang, Wei

    first peoples hosp foshan

  • H

    Hu, Xiao-Hua

    1 · guangxi med univ

  • M

    Ma, Zhi-Gang

    harbin med univ

  • Y

    Yao, Yi-Chen

    chinese acad med sci · sun yat sen univ

  • Z

    Zhuang, Zhi-Xiang

  • Z

    Zhou, Fu-Xiang

  • Y

    Ying, Jie-Er

  • Y

    Yuan, Ying

    2 · zhejiang univ

  • Z

    Zou, Qing-Feng

    guangzhou med univ

  • G

    Guo, Zeng-Qing

    fujian canc hosp · fujian med univ

  • W

    Wu, Xiang-Yuan

    sun yat sen univ

  • J

    Jin, Ying

  • M

    Mai, Zong-Jiong

    sun yat sen univ · chinese acad med sci

  • W

    Wang, Zhi-Qiang

    chinese acad med sci · sun yat sen univ

  • Q

    Qiu, Hong

    huazhong univ sci & technol

  • G

    Guo, Ying

    sun yat sen univ

  • S

    Shi, Si -Mei

    sun yat sen univ · chinese acad med sci

  • C

    Chen, Shuang-Zhen

    sun yat sen univ · chinese acad med sci

  • L

    Luo, Hui-Yan

    sun yat sen univ · chinese acad med sci

  • Z

    Zhang, Dong-Sheng

    sun yat sen univ · chinese acad med sci

  • W

    Wang, Feng-Hua (通讯)

    chinese acad med sci · sun yat sen univ

  • L

    Li, Yu-Hong

    chinese acad med sci · sun yat sen univ

  • X

    Xu, Rui-Hua (通讯)

    chinese acad med sci · sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417